Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,006,342
  • Shares Outstanding, K 115,938
  • Annual Sales, $ 84,450 K
  • Annual Income, $ -68,330 K
  • 60-Month Beta 2.84
  • Price/Sales 11.86
  • Price/Cash Flow N/A
  • Price/Book 2.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.31
  • Number of Estimates 5
  • High Estimate -0.27
  • Low Estimate -0.42
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -72.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.37 +1.67%
on 12/13/19
12.33 -30.98%
on 12/09/19
-1.18 (-12.18%)
since 11/13/19
3-Month
7.70 +10.52%
on 10/10/19
12.33 -30.98%
on 12/09/19
-2.34 (-21.57%)
since 09/13/19
52-Week
6.26 +35.94%
on 02/07/19
13.91 -38.82%
on 04/02/19
-3.06 (-26.45%)
since 12/13/18

Most Recent Stories

More News
Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion by 2024

According to various industry and market publications, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the biggest spenders in this area. Outside of the semiconductor...

CNSP : 3.95 (-1.99%)
AGIO : 46.70 (+2.19%)
PTI : 4.25 (+3.66%)
LLY : 121.53 (-0.14%)
SGMO : 8.51 (-1.96%)
Look for Shares of Sangamo Therapeu to Potentially Rebound after Yesterday's 5.66% Sell Off

Sangamo Therapeu (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $10.86 to a high of $12.33. Yesterday, the shares fell 5.7%, which took the trading range below the 3-day low of...

SGMO : 8.51 (-1.96%)
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating investigational...

THLEY : 101.0000 (-8.18%)
SGMO : 8.51 (-1.96%)
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525...

SGMO : 8.51 (-1.96%)
PFE : 38.33 (-0.54%)
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics

QURE : 73.97 (+7.39%)
BMRN : 80.17 (-0.90%)
SGMO : 8.51 (-1.96%)
SRPT : 132.05 (+31.43%)
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives...

SGMO : 8.51 (-1.96%)
SmarTrend Watching for Potential Pullback in Shares of Sangamo Therapeu After 9.40% Gain

Sangamo Therapeu (NASDAQ:SGMO) traded in a range yesterday that spanned from a low of $11.60 to a high of $11.80. Yesterday, the shares gained 9.4%, which took the trading range above the 3-day high...

SGMO : 8.51 (-1.96%)
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal

Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.

RHHBY : 38.1600 (-0.73%)
BMY : 63.82 (-0.19%)
QURE : 73.97 (+7.39%)
SRPT : 132.05 (+31.43%)
SGMO : 8.51 (-1.96%)
BMRN : 80.17 (-0.90%)
BOLD : 59.40 (+0.05%)
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ALKS : 20.87 (-1.79%)
SGMO : 8.51 (-1.96%)
Arrowhead Pharma has the Best Relative Performance in the Biotechnology Industry (ARWR, AKBA , SGMO , BLUE , CCXI )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 6.39 (+0.63%)
SGMO : 8.51 (-1.96%)
ARWR : 66.46 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade SGMO with:

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

2nd Resistance Point 9.23
1st Resistance Point 8.87
Last Price 8.51
1st Support Level 8.26
2nd Support Level 8.01

See More

52-Week High 13.91
Fibonacci 61.8% 10.99
Fibonacci 50% 10.09
Fibonacci 38.2% 9.18
Last Price 8.51
52-Week Low 6.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar